[Ip-health] BRICS To Fight For Medicine As 'Human Right
pbond at mail.ngo.za
Wed Jun 12 05:19:58 PDT 2013
Ah, is this BRICS or just Brazil, India and SA?
A very very important distinction!
(co-host of brics-from-below - http://ccs.ukzn.ac.za/default.asp?6,37 )
On 6/12/2013 3:39 AM, Gopa Kumar wrote:
> BRICS To Fight For Medicine As 'Human Right
> Taking the fight for access to affordable medicines a step further,
> developing countries including India may join hands to propose a resolution
> on access to medicines at the ongoing session of the United Nations Human
> Rights Council (UNHRC) this week.
> The move is keenly watched by members of the developed block including the
> US and the EU as “access to medicines” as a human rights issue, without
> limiting the list of drugs to the “essential medicines”, may hurt the
> interests of the global multinational pharmaceutical corporations.
> The development follows the recommendation given by Delhi-based legal
> activist Anand Grover, in his capacity as the Council’s Special Rapporteur.
> Grover, who took up this position in 2008, had submitted his report that
> "identifies and analyses challenges and good practices with respect to
> access to medicines in the context of the right-to-health framework" on May
> The special rapporteurs of UNHRC are independent experts appointed by the
> Council to examine and report back on a country situation or a specific
> human rights theme. The position is honorary and the expert is not a staff
> of the United Nations.
> According to Geneva-based officials, Brazil, in its intervention on
> Grover’s report, stated that developing countries including India, Brazil,
> South Africa, Egypt and Thailand will take forward the recommendations of
> the Special Rapporteur and introduce the draft resolution at the Council
> meeting. The draft resolution may request the States, the UN and other
> inter-governmental organisations to address the existing challenges with
> regard to access to medicines in the context of the right to health, and
> the ways to overcome those challenges.
> Taking cue from Grover’s report, it is expected to use the key human rights
> framework on access to medicines, i. e. availability, accessibility,
> acceptability and quality to analyse the international and national
> determinants to access to medicines.
> In the first section of the report, the Special Rapporteur reviews the
> international legal framework as it applies to access to medicines. In the
> second section, he identifies key determinants of access to medicines and
> discusses challenges and good practices with respect to each aspect. The
> key determinants identified in the report are: local production of
> medicines, price regulations, medicines lists, procurement, distribution,
> rational and appropriate use and quality of medicines.
> The report wants the States to ensure transparency of data related to
> quality, safety and efficacy of medicines, including the mandatory
> publication of adverse data; increase budgetary support for national
> regulators and increase recruitment of inspectors at competitive salaries;
> improve South-South cooperation to conduct joint inspections of
> manufacturing facilities and share information and good practices; and
> avoid conflation of poor-quality medicines, a quality control issue, with
> counterfeit medicines, a trade issue.
> The 23rd session of the Human Rights Council is taking place from 27 May to
> 14 June in Geneva and the draft resolution is expected to come up for
> consideration during the week. -
> See more at:
> Ip-health mailing list
> Ip-health at lists.keionline.org
More information about the Ip-health